Search results for "Digestive System"

showing 10 items of 1747 documents

Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia

2014

Idiopathic achalasia is characterized by a failure of the lower esophageal sphincter to relax due to a loss of neurons in the myenteric plexus(1,2). This ultimately leads to massive dilatation and an irreversibly impaired megaesophagus. We performed a genetic association study in 1,068 achalasia cases and 4,242 controls and fine-mapped a strong MHC association signal by imputing classical HLA haplotypes and amino acid polymorphisms. An eight-residue insertion at position 227-234 in the cytoplasmic tail of HLA-DQ beta 1 (encoded by HLA-DQB1*05:03 and HLA-DQB1*06:01) confers the strongest risk for achalasia (P = 1.73 x 10(-19)). In addition, two amino acid substitutions in the. extracellular …

MaleModels MolecularAchalasiaImmunogeneticsBiologyMajor histocompatibility complexPolymorphism Single Nucleotidedigestive systemHLA-DQ alpha-ChainsHLA-DQ AntigensHLA-DQotorhinolaryngologic diseasesGeneticsmedicineHLA-DQ beta-ChainsHumansGenetic Predisposition to DiseaseEsophagusAllelesGenetic Association StudiesGenetic associationGeneticsAchalasiaMotility disorderASSOCIATIONmedicine.diseasedigestive system diseasesEsophageal AchalasiaINSIGHTSLogistic Modelsmedicine.anatomical_structureAmino Acid SubstitutionHaplotypesCase-Control StudiesImmunologybiology.proteinFemaleIdiopathic achalasiageneticMHCNature Genetics
researchProduct

A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients

2015

Background: Infliximab, an anti-tumour necrosis factor approved for treatment of Crohn's disease and ulcerative colitis, is administered at predefined interdose-intervals. On insufficient response or loss of response, treatment can be intensified. The lack or loss of response is likely related to complex pharmacokinetics of infliximab. Aims: To explore optimal dosing strategies of infliximab in treatment-naïve patients with ulcerative colitis through predictive Monte Carlo simulations based on a validated population PK model. Methods: A population of 2,000 treatment-naïve patients was generated by Montecarlo simulation. Six dosing strategies for maintenance therapy were simulated on this po…

MaleModels StatisticalDose-Response Relationship DrugUlcerativeColitisInfliximabTreatment OutcomeGastrointestinal AgentsHumanslcsh:Diseases of the digestive system. GastroenterologyColitis UlcerativeComputer SimulationFemalePharmacokineticslcsh:RC799-869Monte Carlo Method
researchProduct

Arch expansion with the Invisalign system: Efficacy and predictability.

2020

Background In adult patients, treatment of skeletal crossbite requires combined treatment by fixed or removable appliances and orthognathic surgery. In cases of dentoalveolar crossbite, expansion can be achieved with fixed multibrackets and removable transparent aligners. Various researchers have already assessed the Invisalign system’s predictability for arch expansion. However, most of this research was conducted using older appliances, making it necessary to assess the characteristics of the updated system SmartTrack. Material and methods A sample of 114 patients with transverse malocclusion were treated with SmartTrack. The predictability of the system’s software (Clincheck) was assess…

MaleMolarTeethmedicine.medical_treatmentOrthognathic surgeryMandibular first molarMandibular second molar0302 clinical medicineOrthodontic Appliances RemovableMedicine and Health SciencesPremolar030212 general & internal medicineArchMathematicsOrthodonticsMeasurementMultidisciplinaryQRSoftware EngineeringMiddle AgedPrognosisTreatment Outcomemedicine.anatomical_structureCalibrationEngineering and TechnologyMedicineFemaleAnatomyResearch ArticleAdultComputer and Information SciencesAdolescentScienceOral MedicineSurgical and Invasive Medical ProceduresOrthodonticsMolarsComputer SoftwareYoung Adult03 medical and health sciencesDiagnostic MedicinemedicineHumansAgedSoftware ToolsCrossbiteBiology and Life Sciences030206 dentistrymedicine.diseaseJawMalocclusionDigestive SystemHeadMalocclusionSoftwarePLoS ONE
researchProduct

An investigation of the diagnostic, predictive, and prognostic impacts of three colonic biopsy grading systems for acute graft versus host disease.

2021

Acute graft versus host disease (aGvHD) is an important, life-threatening complication after allogeneic hematopoietic stem cell transplantation (alloHSCT). To investigate the value of multiple simultaneous colon biopsies in improving diagnostic accuracy in patients with aGvHD, we retrospectively analyzed 157 patients after alloHSCT. The biopsies were evaluated individually using three established histological grading systems (Lerner, Sale, and Melson). The maximum, minimum, median, and mean histological aGvHD grades were calculated for each patient, and the results were correlated with the Glucksberg grade of clinical manifestation of GvHD, steroid therapy status, and outcome. We found that…

MaleMultivariate analysismedicine.medical_treatmentBiopsyGraft vs Host DiseaseApoptosisHematopoietic stem cell transplantationGastroenterologySteroid TherapyMedicine and Health SciencesMedicineStage (cooking)Multidisciplinarymedicine.diagnostic_testCell DeathPharmaceuticsOrganic CompoundsQRMiddle AgedPrognosisChemistryTreatment OutcomeCell ProcessesAcute DiseasePhysical SciencesMedicineFemaleSteroidsAnatomyResearch ArticleAdultmedicine.medical_specialtyHistologyAdolescentColonScienceSurgical and Invasive Medical ProceduresYoung AdultDrug TherapyInternal medicineBiopsyHumansddc:610Grading (tumors)AgedProportional Hazards Modelsbusiness.industryOrganic ChemistryChemical CompoundsBiology and Life SciencesHistologyEndoscopyCell BiologyEndoscopyGastrointestinal TractMultivariate AnalysisComplicationbusinessDigestive SystemPloS one
researchProduct

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

2013

The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for …

MaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCost effectivenessCost-Benefit AnalysisSettore MED/12 - GASTROENTEROLOGIAAged; Antineoplastic Agents; Carcinoma Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life YearsAntineoplastic AgentsKaplan-Meier EstimateDrug CostsInternal medicinemedicineHumansProspective StudiesProspective cohort studyneoplasmsSurvival rateAgedHepatologyPerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsCarcinomaHepatocellular carcinoma sorafenib ICER cost-effectivenessHepatocellularSorafenibmedicine.diseaseMarkov Chainsdigestive system diseasesSurgeryQuality-adjusted life yearHepatocellular carcinomaMultivariate AnalysisQuality-Adjusted Life YearsbusinessLiver cancermedicine.drugHepatology
researchProduct

Gastritis and gastroesophageal reflux disease are strongly associated with non-allergic nasal disorders

2021

AbstractBackgroundGastroesophageal reflux disease (GERD) has been reported to be significantly associated with chronic rhinosinusitis, but the strength of the association is still debated.AimsTo evaluate the strength of the association between gastritis/GERD and non-allergic rhinitis (NAR)/allergic rhinitis (AR)/sinusitis.MethodsWe investigated 2887 subjects aged 20–84 years, who underwent a clinical visit in seven Italian centres (Ancona, Palermo, Pavia, Terni, Sassari, Torino, Verona) within the study on Gene Environment Interactions in Respiratory Diseases, a population-based multicase-control study between 2008 and 2014. Subjects were asked if they had doctor-diagnosed “gastritis or sto…

MaleNon-allergic rhinitisGastroesophageal reflux diseaseGastroenterologyAllergic rhinitis0302 clinical medicinePrevalenceNon-allergic rhiniti030223 otorhinolaryngologySinusitisRhinitisAged 80 and overeducation.field_of_studyMiddle AgedGastrititItalyGastritisGastroesophageal RefluxFemalePublic HealthGastritismedicine.symptomResearch ArticleAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationGastrititsSettore MED/10 - Malattie Dell'Apparato RespiratorioNOHiatal herniaGastritits Gastroesophageal refux disease Allergic rhinitis Non-allergic rhinitis SinusitisYoung Adult03 medical and health sciencesAllergic rhinitis; Gastritits; Gastroesophageal reflux disease; Non-allergic rhinitis; SinusitisInternal medicineAllergic rhinitimedicineHumansGastroesophageal refux diseaseSinusitiseducationAgedlcsh:RC705-779business.industrylcsh:Diseases of the respiratory systemmedicine.diseaseRhinitis AllergicSinusitidigestive system diseases030228 respiratory systemRelative riskChronic DiseaseGERDAllergic rhinitis; Gastritits; Gastroesophageal reflux disease; Non-allergic rhinitis; Sinusitis Public HealthNon-allergic rhinitisbusinessEsophagitis
researchProduct

Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma.

2016

Abstract Purpose To perform an external validation of the Assessment for Retreatment with Transarterial Chemoembolization (ART) and α-fetoprotein (AFP), Barcelona Clinic Liver Cancer (BCLC), Child–Pugh, and response (ABCR) scores and to compare them in terms of prognostic power. Materials and Methods From 2000 to 2015, 871 patients with hepatocellular carcinoma underwent transarterial chemoembolization at a tertiary referral hospital, and 176 met all inclusion and exclusion criteria for both scores and were analyzed. Nineteen percent (n = 34) had BCLC stage A disease and 81% had stage B disease. Thirty-nine patients (22%) presented with elevated AFP levels. Overall survival was calculated. …

MaleOncologyCancer ResearchMultivariate analysisKaplan-Meier EstimateGastroenterologyTertiary Care Centers0302 clinical medicineRisk FactorsMedicineStage (cooking)Aged 80 and overLiver NeoplasmsMiddle AgedTreatment OutcomeOncologyBrier score030220 oncology & carcinogenesisPredictive value of testsHepatocellular carcinomaRetreatmentInclusion and exclusion criteriaFemale030211 gastroenterology & hepatologyalpha-FetoproteinsCardiology and Cardiovascular MedicineAlpha-fetoproteinLiver cancerAdultmedicine.medical_specialtyTreatment responseCarcinoma HepatocellularClinical Decision-MakingTertiary referral hospitalRisk AssessmentDecision Support TechniquesYoung Adult03 medical and health sciencesPredictive Value of TestsInternal medicineHumansRadiology Nuclear Medicine and imagingAspartate AminotransferasesChemoembolization TherapeuticAgedNeoplasm StagingRetrospective StudiesHepatologybusiness.industryPatient SelectionExternal validationReproducibility of ResultsRetrospective cohort studymedicine.diseaseConfidence intervalBCLC Stagedigestive system diseasesSurgerybusinessJournal of Clinical Oncology
researchProduct

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuxim…

2012

Purpose To evaluate the addition of cetuximab to neoadjuvant chemotherapy before chemoradiotherapy in high-risk rectal cancer. Patients and Methods Patients with operable magnetic resonance imaging–defined high-risk rectal cancer received four cycles of capecitabine/oxaliplatin (CAPOX) followed by capecitabine chemoradiotherapy, surgery, and adjuvant CAPOX (four cycles) or the same regimen plus weekly cetuximab (CAPOX+C). The primary end point was complete response (CR; pathologic CR or, in patients not undergoing surgery, radiologic CR) in patients with KRAS/BRAF wild-type tumors. Secondary end points were radiologic response (RR), progression-free survival (PFS), overall survival (OS), an…

MaleOncologyCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentCetuximabKaplan-Meier Estimatemedicine.disease_causeDeoxycytidineGastroenterologyIntestinal mucosaAntineoplastic Combined Chemotherapy ProtocolsIntestinal MucosaColectomyNeoadjuvant therapyCetuximabAntibodies MonoclonalMiddle AgedCombined Modality TherapyNeoadjuvant TherapyOxaliplatinTreatment OutcomeOncologyFemaleFluorouracilKRASmedicine.drugAdultmedicine.medical_specialtyAdenocarcinomaAntibodies Monoclonal HumanizedRisk AssessmentDisease-Free SurvivalCapecitabineInternal medicinePreoperative CaremedicineHumansNeoplasm InvasivenessneoplasmsCapecitabineAgedNeoplasm StagingAnalysis of VarianceRectal Neoplasmsbusiness.industryChemoradiotherapy Adjuvantmedicine.diseaseSurvival AnalysisUnited Kingdomdigestive system diseasesOxaliplatinLogistic ModelsRadiotherapy AdjuvantbusinessChemoradiotherapyFollow-Up StudiesJournal of Clinical Oncology
researchProduct

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in pat…

2013

Abstract Background This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction. Methods Patients received neoadjuvant radiotherapy (50.4 Gy) together with weekly docetaxel (20 mg/m2 at dose level (DL) 1 and 2, 25 mg/m2 at DL 3) and oxaliplatin (40 mg/m2 at DL 1, 50 mg/m2 at DL 2 and 3) over 5 weeks. The primary endpoint was the DLT and the MTD of the RCT regimen. Secondary endpoints included overall response rate (ORR) and progression-free survival (PFS). Results A total of 24 patients were included. F…

MaleOncologyCancer ResearchTime FactorsEsophageal NeoplasmsOrganoplatinum Compoundsmedicine.medical_treatmentMedizinKaplan-Meier EstimateDocetaxellaw.inventionRandomized controlled triallawGermanyProspective StudiesIsraelProspective cohort studyNeoadjuvant therapyChemoradiotherapyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensNeoadjuvant TherapyOxaliplatinOesophagogastric cancer oxaliplatinTreatment OutcomeDocetaxelOncologyNeoadjuvant radiochemotherapyAdenocarcinomaFemaleTaxoidsEsophagogastric JunctiontherapeuticsResearch Articlemedicine.drugAdultmedicine.medical_specialtyMaximum Tolerated DoseAntineoplastic AgentsAdenocarcinomalcsh:RC254-282Disease-Free SurvivalStomach NeoplasmsInternal medicinemedicineGeneticsHumansddc:610neoplasmsAgedDose-Response Relationship Drugbusiness.industryChemoradiotherapy Adjuvantmedicine.diseasedigestive system diseasesOxaliplatinClinical trialbusinessChemoradiotherapy
researchProduct

Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas

2020

Abstract Background Small bowel adenocarcinoma is a relatively rare cancer, often diagnosed in an advanced stage. In localized and resectable disease, surgery alone or in combination with adjuvant chemotherapy is the mainstay of treatment. In the recently published National Comprehensive Cancer Network Clinical Practice guidelines, criteria for selecting patients with stage II small bowel adenocarcinoma to receive adjuvant chemotherapy are provided, and they are mainly extrapolated from studies on colorectal cancer. Patients and Methods In the present study, we aimed to verify whether mismatch repair deficiency phenotype, high-risk pathologic features (including T4, positive resection margi…

MaleOncologyColorectal cancerDNA Mismatch RepairCOLORECTAL-CANCERSettore MED/120302 clinical medicinePMS2small bowel adenocarcinomaMismatch Repair Endonuclease PMS20303 health sciencesPrognosisMMRMutS Homolog 2 ProteinOncologyCARCINOMAS030220 oncology & carcinogenesisimmunohistochemistryMismatch Repair Status small bowel adenocarcinomaFemaleMicrosatellite InstabilityDNA mismatch repairMutL Protein Homolog 1Colorectal Neoplasmsstage IImedicine.medical_specialtyhigh-risk pathologic featuresDNA Mismatch Repair; Female; Humans; Male; Microsatellite Instability; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Prognosis; Adenocarcinoma; Colorectal Neoplasmssmall bowel adenocarcinoma; mismatch repair statusAdenocarcinomaNO03 medical and health sciencessmall bowel carcinomahistotypeInternal medicineTranslational ResearchmedicineHumansmismatch repair status030304 developmental biologysmall bowel adenocarcinomasbusiness.industryCancerMicrosatellite instabilityMismatch Repair ProteinAdenocarcinoma IBD Cancermedicine.diseasedigestive system diseasesMSH6COLORECTAL-CANCER; CARCINOMAS; CONSENSUSsmall bowel carcinoma MMR immunohistochemistryMismatch repair Small bowel AdenocarcinomaMSH2Mismatch repair status; stage II; small bowel adenocarcinomas; histotype; high-risk pathologic featuresSurgeryCONSENSUSbusiness
researchProduct